Fig. 3: UBE3C-LRP5 (v7) fusion has transforming potential in vivo and promotes metastasis in vitro.
From: Recurrent UBE3C-LRP5 translocations in head and neck cancer with therapeutic implications
a In vivo tumorigenicity assay performed using NOD-SCID mice subcutaneously injected with NIH/3T3 cells stably overexpressing the empty vector (n = 6) or UBE3C-LRP5 (v7) fusion variant (n = 6). The number of mice with the tumors is mentioned on the top of the mice images. b Clonogenic cell survival assay of AW13516 (top panel) and AW8507 (bottom panel) cells stably expressing empty vector or UBE3C-LRP5. The bar plots on the right indicate the number of colonies formed in each group. c–e Cell migration (top panels) and invasion assay (bottom panels) of AW13516- (c), AW8507- (d), and NIH/3T3- (e) cells stably expressing empty vector or UBE3C-LRP5 (v7) fusion. The bar plots depict the number of cells migrated or invaded in vector control and UBE3C-LRP5 (v7) fusion-expressing clones. Data were shown as means ± SD. p values are from the Student’s unpaired t-test and denoted as *p < 0.05; **p < 0.01; ****p < 0.0001. The data shown are representative of n = 3 independent experiments. Scale bar = 400 µM.
